These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11588130)

  • 1. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
    Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
    Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
    Decensi A; Bonanni B; Baglietto L; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Robertson C; Marinucci I; Mariette F; Sandri MT; Daldoss C; Bianco V; Buttarelli M; Cazzaniga M; Franchi D; Cassano E; Omodei U
    Clin Cancer Res; 2004 Jul; 10(13):4389-97. PubMed ID: 15240527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
    Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
    Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
    Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factors and breast cancer risk in Chinese women.
    Yu H; Jin F; Shu XO; Li BD; Dai Q; Cheng JR; Berkel HJ; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):705-12. PubMed ID: 12163322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
    Guerrieri-Gonzaga A; Robertson C; Bonanni B; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Formelli F; Intra M; Latronico A; Franchi D; Pelosi G; Johnson K; Decensi A
    J Clin Oncol; 2006 Jan; 24(1):129-35. PubMed ID: 16382122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.
    Giovannucci E; Pollak MN; Platz EA; Willett WC; Stampfer MJ; Majeed N; Colditz GA; Speizer FE; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):345-9. PubMed ID: 10794477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women.
    Grønbaek H; Flyvbjerg A; Mellemkjaer L; Tjønneland A; Christensen J; Sørensen HT; Overvad K
    Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1759-64. PubMed ID: 15533904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
    Serrano D; Baglietto L; Johansson H; Mariette F; Torrisi R; Onetto M; Paganuzzi M; Decensi A
    Clin Cancer Res; 2005 Mar; 11(5):2083-8. PubMed ID: 15756035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays.
    Rinaldi S; Kaaks R; Zeleniuch-Jacquotte A; Arslan AA; Shore RE; Koenig KL; Dossus L; Riboli E; Stattin P; Lukanova A; Toniolo P
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):48-52. PubMed ID: 15668475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer.
    Serrano ML; Romero A; Cendales R; Sánchez-Gómez M; Bravo MM
    Biomedica; 2006 Jun; 26(2):258-68. PubMed ID: 16925098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial.
    Fairey AS; Courneya KS; Field CJ; Bell GJ; Jones LW; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):721-7. PubMed ID: 12917202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of insulin-like growth factor I and insulin-like growth factor-binding protein-3 with intelligence quotient among 8- to 9-year-old children in the Avon Longitudinal Study of Parents and Children.
    Gunnell D; Miller LL; Rogers I; Holly JM;
    Pediatrics; 2005 Nov; 116(5):e681-6. PubMed ID: 16263982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
    Oh JC; Wu W; Tortolero-Luna G; Broaddus R; Gershenson DM; Burke TW; Schmandt R; Lu KH
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):748-52. PubMed ID: 15159305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.